| pubmed-article:19238326 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19238326 | lifeskim:mentions | umls-concept:C0206745 | lld:lifeskim |
| pubmed-article:19238326 | lifeskim:mentions | umls-concept:C1704939 | lld:lifeskim |
| pubmed-article:19238326 | lifeskim:mentions | umls-concept:C0242643 | lld:lifeskim |
| pubmed-article:19238326 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:19238326 | lifeskim:mentions | umls-concept:C0743223 | lld:lifeskim |
| pubmed-article:19238326 | lifeskim:mentions | umls-concept:C1311070 | lld:lifeskim |
| pubmed-article:19238326 | lifeskim:mentions | umls-concept:C0388976 | lld:lifeskim |
| pubmed-article:19238326 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19238326 | pubmed:dateCreated | 2010-3-3 | lld:pubmed |
| pubmed-article:19238326 | pubmed:abstractText | Trabectedin is a novel anticancer drug active against soft tissue sarcomas. Trabectedin is a substrate for P-glycoprotein (P-gp), which is encoded by mdr1a/1b in rodents. Plasma and tissue distribution, and excretion of [(14)C]-trabectedin were evaluated in wild-type and mdr1a/1b(-/-) mice. In parallel, we investigated the toxicity profile of trabectedin by serial measurements of blood liver enzymes and general pathology. [(14)C]-trabectedin was extensively distributed into tissues, and rapidly converted into a range of unknown metabolic products. The excretion of radioactivity was similar in both genotypes. The plasma clearance of unchanged trabectedin was not reduced when P-gp was absent, but organs under wild type circumstances protected by P-gp showed increased trabectedin concentrations in mdr1a/1b(-/-) mice. Although hepatic trabectedin concentrations were not increased when P-gp was absent, mdr1a/1b(-/-) mice experienced more severe liver toxicity. P-gp plays a role in the in vivo disposition and toxicology of trabectedin. | lld:pubmed |
| pubmed-article:19238326 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19238326 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19238326 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19238326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19238326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19238326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19238326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19238326 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19238326 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:19238326 | pubmed:issn | 1573-0646 | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:BeijnenJ HJH | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:RosingHH | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:BeumerJ HJH | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:Lopez-LazaroL... | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:SchellensJ... | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:BuckleTT | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:FrankeN ENE | lld:pubmed |
| pubmed-article:19238326 | pubmed:author | pubmed-author:TolboomRR | lld:pubmed |
| pubmed-article:19238326 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19238326 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:19238326 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19238326 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19238326 | pubmed:pagination | 145-55 | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:meshHeading | pubmed-meshheading:19238326... | lld:pubmed |
| pubmed-article:19238326 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19238326 | pubmed:articleTitle | Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. | lld:pubmed |
| pubmed-article:19238326 | pubmed:affiliation | Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. beumerjh@upmc.edu | lld:pubmed |
| pubmed-article:19238326 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19238326 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
